Übernahme durch Pfizer?

Pfizer forged in 2007 a research and licensing deal with Icagen, relating to medicines to treat pain and related disorders. The biotech is based in Research Triangle Park, North Carolina.

Pfizer said ongoing talks with Icagen could lead to an extension or amendment of their longstanding agreement. The drugmaker said a strategic transaction could influence or change control of Icagen "by means of a stock or asset acquisition or merger."

Icagen, in a release late on Friday, acknowledged it is engaged in preliminary discussions with Pfizer regarding a potential strategic transaction. But it noted there can be no assurance any agreement will be reached. (Reporting by Ransdell Pierson; editing by Andre Grenon)

www.reuters.com/article/2011/06/24/...ealthcareNews&rpc=43

www.nasdaq.com/aspxcontent/...;selected=ICGN&mkttype=after

messages.finance.yahoo.com/mb/ICGN

Ich würde nicht in Deutschland kaufen da die Makler in Berlin und in FRankfurt absolut beschissen herum taxen und und diese immer weiter erhöhen.

Ich denke das da schon jemand einsteigen will und die Makler deshalb so blöd hochtaxen.

Nachbörslich Schlußkurs in den USA 4,80 Dollar entspricht hier in D einen Eurokurs von 3,38 Euro und man darf nicht vergessen das die 4,80 Dollar auch schon ein 100% Aufschlag auf den ECHTEN Schlußkurs in den USA von 2,40 Dollar waren.

Also überlegt gut und wartet gegebenenfalls die Eröffnung in den USA ab.

Also ich kenne Dich und finde deine Art hier unterste Schublade tut mir leid.

Nur weil Dich die Aktie nicht interessiert weil Du vielleicht nicht in solche Werte investierst brauchst Du noch lange nicht schwarze Sterne vergeben.

Lies Dir mal die Boardregeln durch wofür die schwarzen Sterne denn sind.Als langjähriges Mitglied hier bei Ariva solltest Du dies wissen und auch so handhaben.

Bist hier im überigen gesperrt.

In den USA setzt dich der nachbörsliche Trend von gestern weiter fort.

Bis jetzt schon gut 2,5 Millionen Aktien gehandelt von den 7,5 Millionen die es insgesamt gibt.Davon sind ja schon 1,1 Millionen bei Pfizer.

Bin gespannt obs es baldige NEWS gibt zu einer eventuellen Übernahme?

rt 5,42 Dollar

Kommen nach Börsenschluß NEWS??

Gibts morgen nochmals so einen Schub wenn nachbörslich kein Übernahmeangebot kommt??

Liegt so ein Übernahmeangebot wirklich wie in den Ami-Boards vermutet bei mindestens 15 Dollar?

Herrlich hier.

Heute morgen Kauflimit von 5 Dollar in den USA gesetzt.

Dann schon die 32 Grad zum schwimmen genutzt und ich komme wieder und sehe der Kauf ist Gott sei Dank durchgegangen.

Jetzt steht die Aktie schon über 6 Dollar was mein Tagesziel(Hoffung für heute ) war.

Im Yahoo-Board spricht bei den wenigen Shares die gehandelt werden können schon von einem Squezze der heute noch kommen könnte.Die Aktie könnte dadurch heute noch auf 10 Dollar gehen vermuten einige.

Mal abwarten hab nen Stop drin bei 5,25 Dollar und warte einfach die Tage ab.

Ein seriöser Analyst sieht dort bei ca. 100 Millionen Dollar ein faires Übernahmeangebot.


"I think an acquisition is very reasonable... a deal value of around $100 million is a possibility," McNicoll, Lewis & Vlak analyst Christopher James said.

ya cant go from from 2.5 to 13 or pfe holders would sue, so you preannounce and go from there, funny that 6.5 x 2 = 13

pfe has had their filings and more for some time, they have asked for other proprietary items to confirm company statements, that done, they wont wait to pull the trigger lest they give competitors time to act

Das wären nochmals 110% vom jetzigen Kurs gesehen.

Mal schauen wies heute mittag läuft.Es könnte spannend werden ob der Aufwärtstrend wirklich fortgesetzt wird oder ob doch eine Konso eintritt.

seekingalpha.com/news-article/...t-buzz-pain-and-more-on-table

Icagen Pops on Pfizer Buyout Buzz: Pain and More on Table


Shares of Icagen Inc. popped more than 150 percent in early trading Monday on news that the biotech is engaged in preliminary buyout discussions with long-time partner Pfizer Inc. (PFE)

Late Friday, Pfizer filed a Schedule 13-D revealing that, as part of its ongoing evaluation of its deal with Icagen, the big pharma is "evaluating the possibility of entering into a strategic transaction with Icagen . . . by means of a stock or asset acquisition or merger." A confidentiality agreement has been signed and due diligence is under way.

Icagen subsequently issued its own press release acknowledging that it is "currently engaged in preliminary discussions with Pfizer" but that no definitive agreement has been reached.

Despite the cautionary language, Icagen investors were stoked. Shares of the Research Triangle Park, N.C.-based biotech (NASDAQ:ICGN) popped to a new 52-week high on Monday and closed at $6.33, a gain of 163.8 percent, or $3.93, for the day.

Pfizer and Icagen signed a billion-dollar deal in 2007 for rights to Icagen's sodium ion channel modifiers in pain indications. The deal covered compounds targeting three specific ion channels, and Icagen stands to get up to $359 million in research, development, regulatory and commercialization milestones for each product, plus royalties. (See BioWorld Today, Aug. 15, 2007.)

The deal was extended in 2009 and again in 2010. Pfizer bought stock in Icagen as part of the deal and currently owns 1 .07 million shares about 14 percent of the biotech.

Late last year, Pfizer and Icagen said they had picked a compound targeting the sodium ion channel Nav1 .7 as their lead candidate for clinical studies. That brought $1 million to Icagen and sent the biotech's stock up 78.7 percent. (See BioWorld Today, Dec. 1 , 2010.)

Icagen needed the good news: The biotech had suffered several setbacks over the past few years including Johnson & Johnson bailing on a partnership after the failure of senicapoc in a Phase III sickle cell trial, Bristol-Myers Squibb Co. dropping work on an atrial fibrillation compound, a Phase II failure of senicapoc in asthma, and a clinical hold on epilepsy compound ICA-105665.

Pfizer needs some good news, too, particularly in its pain pipeline. Last year, the big pharma suspended a massive clinical program for anti-NGF antibody tanezumab in osteoarthritis pain. Pfizer was running some 19 clinical trials in upward of 9,000 patients at the time of the suspension. Last year's acquisition of King Pharmaceuticals Inc. went a long way toward filling the pain pipeline gap, but last week's receipt of another complete response letter for Remoxy (extended-release oxycodone) was another tough blow. (See BioWorld Today, June 25, 2010, Oct. 13, 2010, and June 27, 2011 .)

If Pfizer does acquire Icagen, it would get more than the pain program on which the two companies already collaborate.

Icagen recently made steps toward getting ICA-105665 back on track in epilepsy. The FDA removed the clinical hold on the drug, which previously met its primary endpoint in a Phase IIa study measuring its ability to reduce the photic-induced epileptiform EEG response in patients with epilepsy. (See BioWorld Today, March 17, 2010.)

More good news: ICA-105665 is a KCNQ potassium channel agonist, and earlier this month the FDA approved Valeant Pharmaceuticals International Inc. and partner GlaxoSmithKline plc's epilepsy drug Potiga (ezogabine), which also acts at KCNQ ion channels and may help validate the approach. (See BioWorld Today, June 14, 2011.)

Earlier in its pipeline, Icagen is in preclinical development with compounds targeting ion channels associated with inflammatory disease.

(c) 2011 Thomson BioWorld, All Rights Reserved.

www.newsobserver.com/2011/06/28/1306163/....html#ixzz1QYuKOCTk

denn bisher hat es sich stark gelohnt zu investieren.

So wie ich die Umsätze der letzten Wochen sehe steht hier wirklich was großes an mit Pfizer.

Eine Übernahme oder eine riesige Beteidigung an ICAGEN (bisher hat Pfizer 14%).

Wir werden es sicherlich bald erfahren.

da kann man nichts machen.

6 Dollar gibt es nur von Pfizer hier die NEWS.

Pfizer To Acquire Icagen

Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is approximately $56 million.

www.thestreet.com/story/11191281/1/...r-to-acquire-icagen.html